Quantum BioPharma Ltd. (CSE:QNTM)
13.00
+0.21 (1.64%)
At close: May 25, 2026
Quantum BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.34 | 1.91 | 6 | 2.76 | 16.98 | 35.26 |
Short-Term Investments | 0.22 | 0.46 | 1.2 | 0.76 | - | 0.16 |
Cash & Short-Term Investments | 4.56 | 2.36 | 7.2 | 3.51 | 16.98 | 35.42 |
Cash Growth | 28.98% | -67.15% | 104.89% | -79.31% | -52.06% | 102.10% |
Accounts Receivable | - | - | 3.43 | 7.19 | 0.02 | - |
Other Receivables | 0.21 | 0.23 | 0.37 | 0.23 | 0.37 | 0.5 |
Receivables | 0.21 | 0.23 | 3.81 | 7.42 | 0.4 | 0.5 |
Inventory | 0.05 | 0.05 | 0.12 | - | - | - |
Prepaid Expenses | 0.08 | 0.02 | 0.04 | 0.12 | 0.16 | 0.76 |
Other Current Assets | 5.47 | 3.82 | 0.89 | 0.03 | 0.31 | 9.25 |
Total Current Assets | 10.37 | 6.48 | 12.05 | 11.09 | 17.85 | 45.93 |
Property, Plant & Equipment | 0.15 | 0.17 | 0.13 | 0.12 | 0.26 | 0.17 |
Long-Term Investments | - | - | 0 | 0.01 | 0.83 | 0.66 |
Other Intangible Assets | 4.41 | 4.51 | 4.93 | 5.36 | 12.04 | 16.2 |
Long-Term Accounts Receivable | - | - | - | 0.91 | 7.43 | - |
Total Assets | 14.93 | 11.16 | 17.12 | 17.47 | 38.41 | 62.96 |
Accounts Payable | 3.59 | 1.98 | 3.25 | 3.24 | 2.76 | 3 |
Accrued Expenses | - | 2.2 | 1.11 | 0.95 | 4.35 | 4.46 |
Short-Term Debt | 0.3 | 1.3 | 0.62 | 0.3 | 0.3 | 0.3 |
Current Portion of Long-Term Debt | 0.49 | 0.47 | 0.15 | - | - | - |
Current Portion of Leases | 0.08 | 0.1 | 0.05 | 0.04 | 0.18 | 0.12 |
Current Unearned Revenue | - | - | 1 | - | - | - |
Other Current Liabilities | 11.88 | - | 0.49 | 0.03 | 0.24 | 0.83 |
Total Current Liabilities | 16.35 | 6.06 | 6.68 | 4.57 | 7.83 | 8.7 |
Long-Term Leases | - | - | - | - | 0.04 | 0.13 |
Total Liabilities | 16.35 | 6.06 | 6.68 | 4.57 | 7.87 | 8.83 |
Common Stock | 177.49 | 169.7 | 150.47 | 137.78 | 143.41 | 152.32 |
Additional Paid-In Capital | 34.74 | 35.41 | 31.07 | 30.23 | 28.5 | 22.58 |
Retained Earnings | -211.85 | -198.29 | -172.11 | -157.91 | -144.16 | -126.15 |
Comprehensive Income & Other | 0.21 | 0.1 | 2.05 | 3.14 | 2.8 | 5.38 |
Total Common Equity | 0.6 | 6.92 | 11.48 | 13.24 | 30.54 | 54.13 |
Minority Interest | -2.02 | -1.82 | -1.04 | -0.33 | - | - |
Shareholders' Equity | -1.42 | 5.1 | 10.44 | 12.91 | 30.54 | 54.13 |
Total Liabilities & Equity | 14.93 | 11.16 | 17.12 | 17.47 | 38.41 | 62.96 |
Total Debt | 0.87 | 1.88 | 0.82 | 0.34 | 0.52 | 0.56 |
Net Cash (Debt) | 3.69 | 0.49 | 6.37 | 3.17 | 16.46 | 34.86 |
Net Cash Growth | 63.56% | -92.34% | 100.80% | -80.72% | -52.77% | 104.90% |
Net Cash Per Share | 0.97 | 0.15 | 5.61 | 5.21 | 27.63 | 64.84 |
Filing Date Shares Outstanding | 4.49 | 5.83 | 2.71 | 0.62 | 0.63 | 0.59 |
Total Common Shares Outstanding | 4.49 | 3.89 | 2.3 | 0.61 | 0.59 | 0.62 |
Working Capital | -5.98 | 0.42 | 5.37 | 6.52 | 10.02 | 37.23 |
Book Value Per Share | 0.13 | 1.78 | 4.99 | 21.85 | 51.56 | 86.98 |
Tangible Book Value | -3.81 | 2.41 | 6.55 | 7.88 | 18.5 | 37.93 |
Tangible Book Value Per Share | -0.85 | 0.62 | 2.85 | 13.01 | 31.23 | 60.95 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.